LT
LTUS.US Lotus Pharmaceuticals Inc
- Market cap
- USD 8.20M
- P/E
- -
- P/B
- 0.01x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LTUS.US undervalued?
Graham numberThe Graham number of Lotus Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lotus Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Lotus Pharmaceuticals Inc yet.
Lotus Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lotus Pharmaceuticals Inc
Lotus Pharmaceuticals, Inc. operates as a high-conviction pharmaceutical and healthcare investment and industry integration company. The company focuses on building a asset portfolio across the global pharmaceutical and healthcare value chain through global strategic investments, mergers and acquisitions, and industry consolidation. It seeks opportunities across pharmaceuticals and biologics, biopharmaceutical services (CRO/CDMO), oncology pharmaceuticals, medical institutio…
Full company profileLotus Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lotus Pharmaceuticals Inc annual financial statements
| Item | 2008 | 2009 | 2010 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 73.8M | 56.5M | 72.7M | - | - | - | - | - | - | - | - |
| Gross Profit | 33.4M | 32.5M | 39.8M | - | - | - | - | - | - | - | - |
| Operating Income | 15.1M | 19.3M | 21.3M | -21.8K | -6.28K | -30.4K | -21.1K | -18.8K | -13.9K | -29.0K | -13.7K |
| EBITDA | 15.4M | 20.9M | 17.5M | -21.8K | -6.28K | -30.4K | -21.1K | -18.8K | 111K | -29.0K | -13.7K |
| Net Income | 12.8M | 16.4M | 14.4M | -21.8K | -6.28K | -30.4K | -21.1K | -18.8K | 111K | -29.0K | -13.7K |
| EPS | 0.53 | 0.33 | 0.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 63.7M | 84.4M | 103M | 8.54K | 1.74K | 7.67K | 4.81K | 5.68K | - | - | - |
| Total Liabilities | 18.6M | 18.6M | 14.2M | 30.4K | 39.3K | 75.6K | 97.0K | 117K | - | - | - |
| Shareholders' Equity | 45.1M | 65.8M | 89.0M | -21.8K | -37.6K | -68.0K | -92.2K | -111K | - | - | - |
| Cash & Short-term Investments | 1.28M | 3.95M | 1.34M | 31.00 | 1.74K | 7.67K | 1.15K | 1.90K | - | - | - |
| Total Debt | 5.06M | 5.94M | 5.24M | 30.4K | 39.3K | 75.6K | 96.8K | 117K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 37.4M | 31.4M | 26.8M | -21.8K | -6.28K | -30.4K | -23.8K | -19.1K | - | - | -15.4K |
| Capital Expenditure | 39.0M | 28.7M | 29.4M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | 0.00 |
| Free Cash Flow | -1.63M | 2.66M | -2.67M | -21.8K | -6.28K | -30.4K | -23.8K | -19.1K | - | - | -16.5K |
| Ratios | |||||||||||
| ROE | 28.3% | 25.0% | 16.2% | - | - | - | - | - | - | - | - |
| ROA | 20.1% | 19.5% | 14.0% | -255.6% | -360.5% | -396.5% | -438.6% | -331.1% | - | - | - |
| Net Profit Margin | 17.3% | 29.1% | 19.8% | - | - | - | - | - | - | - | - |
| Debt to Equity | 0.11x | 0.09x | 0.06x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lotus Pharmaceuticals Inc dividends
Lotus Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:2 on Dec 31, 2010.
Who owns Lotus Pharmaceuticals Inc
Ownership data of Lotus Pharmaceuticals Inc is not available yet.
Lotus Pharmaceuticals Inc company profile
- Company name
- Lotus Pharmaceuticals Inc
- Ticker
- LTUS.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Pharmaceuticals
- Employees
- 233
- Fiscal year end
- December
- Address
- 127 Leafy Twig, Irvine, CA, United States, 92618
- Phone
- 949 591 3688
- Website
- lotuspharmaceuticalsusa.com
About Lotus Pharmaceuticals Inc
Lotus Pharmaceuticals, Inc. operates as a high-conviction pharmaceutical and healthcare investment and industry integration company. The company focuses on building a asset portfolio across the global pharmaceutical and healthcare value chain through global strategic investments, mergers and acquisitions, and industry consolidation. It seeks opportunities across pharmaceuticals and biologics, biopharmaceutical services (CRO/CDMO), oncology pharmaceuticals, medical institutions, medical devices and diagnostics, digital health, smart elderly care, AI-powered healthcare technologies, internet-based medical services, and new-technology medical aesthetics. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc. is based in Irvine, California.
Lotus Pharmaceuticals Inc management
3- Dr. Zhong Yi LiuFounder, Chairman, Chief Executive Officer and President · born 1961
- Ms. Yan ZengChief Financial Officer and Principal Accounting Officer · born 1969
- Dr. Xing Shen Ph.D.Vice President of Corporate Development · born 1971